Exact Mass: 433.1572378

Exact Mass Matches: 433.1572378

Found 500 metabolites which its exact mass value is equals to given mass value 433.1572378, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

N-acetylaspartylglutamylglutamic acid

N-Acetylaspartylglutamylglutamate; N-Acetyl-L-aspartyl-L-glutamyl-L-glutamate; NAAG2

C16H23N3O11 (433.13325280000004)

Meleagrine

C23H23N5O4 (433.17499580000003)

An indole alkaloid with a heterotetracyclic skeleton isolated from Penicillium oxalicum.

Dihydrozeatin riboside monophosphate

C15H24N5O8P (433.1362434)

Tolmetin glucuronide

(2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-({2-[1-methyl-5-(4-methylbenzoyl)-1H-pyrrol-2-yl]acetyl}oxy)oxane-2-carboxylic acid

C21H23NO9 (433.1372748)

Tolmetin glucuronide belongs to the family of Glucuronic Acid Derivatives. These are compounds containing a glucuronic acid moeity (or a derivative), which consists of a glucose moiety with the C6 carbon oxidized to a carboxylic acid.

4-Hydroxy-5-[3-(sulfooxy)phenyl]pentanoylcarnitine

3-({4-hydroxy-5-[3-(sulfooxy)phenyl]pentanoyl}oxy)-4-(trimethylazaniumyl)butanoate

C18H27NO9S (433.1406452)

4-hydroxy-5-[3-(sulfooxy)phenyl]pentanoylcarnitine is an acylcarnitine. More specifically, it is an 4-hydroxy-5-[3-(sulfooxy)phenyl]pentanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 4-hydroxy-5-[3-(sulfooxy)phenyl]pentanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 4-hydroxy-5-[3-(sulfooxy)phenyl]pentanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

(2R)-1-[4-[1,3-Benzothiazol-2-yl(methyl)amino]piperidin-1-yl]-3-(3,4-difluorophenoxy)propan-2-ol

C22H25F2N3O2S (433.1635454)

Amustaline

(N,N-Bis(2-chloroethyl))-2-aminoethyl-3-((acridin-9-yl)amino)propionate

C22H25Cl2N3O2 (433.132373)

D000970 - Antineoplastic Agents > D018906 - Antineoplastic Agents, Alkylating > D009588 - Nitrogen Mustard Compounds C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent

Arg-gly-asp-ser

3-({2-[(2-amino-5-carbamimidamido-1-hydroxypentylidene)amino]-1-hydroxyethylidene}amino)-3-[(1-carboxy-2-hydroxyethyl)-C-hydroxycarbonimidoyl]propanoate

C15H27N7O8 (433.19210219999997)

Brexpiprazole

7-{4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy}-1,2-dihydroquinolin-2-one

C25H27N3O2S (433.18238820000005)

D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents Brexpiprazole (OPC-34712), an atypical orally active antipsychotic agent, is a partial agonist of human 5-HT1A and dopamine D2L receptor with Kis of 0.12 nM and 0.3 nM, respectively. Brexpiprazole is also a 5-HT2A receptor antagonist with a Ki of 0.47 nM. Brexpiprazole also shows potent antagonist activity at human noradrenergic α1B (Ki=0.17 nM) and α2C receptors (Ki=0.59 nM)[1][2].

(2S)-2-[[4-[[(2R)-2-Amino-3-sulfanylpropyl]amino]-2-phenylbenzoyl]amino]-4-methylsulfanylbutanoic acid

(2S)-2-[[4-[[(2R)-2-Amino-3-sulphanylpropyl]amino]-2-phenylbenzoyl]amino]-4-methylsulphanylbutanoic acid

C21H27N3O3S2 (433.14937520000007)

7-[(Gly-L-Phe-)Amino]-4-(trifluoromethyl)-2H-1-benzopyran-2-one

2-(2-aminoacetamido)-N-[2-oxo-4-(trifluoromethyl)-2H-chromen-7-yl]-3-phenylpropanamide

C21H18F3N3O4 (433.12493440000003)

2-Methyl-1-(2-methyl-3-(trifluoromethyl)benzyl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid

2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(morpholin-4-yl)-1H-1,3-benzodiazole-4-carboxylic acid

C22H22F3N3O3 (433.1613178)

C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C2152 - Phosphatidylinositide 3-Kinase Inhibitor C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor D000970 - Antineoplastic Agents

4-Nitrophenyl 4-(3-phenoxybenzyl)piperazine-1-carboxylate

4-Nitrophenyl 4-[(3-phenoxyphenyl)methyl]piperazine-1-carboxylic acid

C24H23N3O5 (433.16376280000003)

1-(2-Methyl-4-methoxyphenyl)-4-((2-hydroxyethyl)amino)-6-trifluoromethoxy-2,3-dihydropyrrolo(3,2-c)quinoline

1-(4-Methoxy-2-methylphenyl)-4-((2-hydroxyethyl)amino)-6-trifluoromethoxy-2,3-dihydropyrrolo(3,2-c)quinoline

C22H22F3N3O3 (433.1613178)

D004791 - Enzyme Inhibitors > D054328 - Proton Pump Inhibitors

2-[(Acridin-9-ylamino)methyl]-4-[bis(2-chloroethyl)amino]butanoic acid

4-[Bis(2-chloroethyl)amino]-2-{[(9,10-dihydroacridin-9-ylidene)amino]methyl}butanoate

C22H25Cl2N3O2 (433.132373)

Sarpicillin

Methoxymethyl 6-(2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid

C21H27N3O5S (433.1671332000001)

D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D010406 - Penicillins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams

N-(((1-(2-(Diethylamino)ethyl)amino)-9-oxo-9H-thioxanthen-4-yl)methyl)methanesulfonamide

N-[(1-{[2-(diethylamino)ethyl]amino}-9-oxo-9H-thioxanthen-4-yl)methyl]methanesulphonamide

C21H27N3O3S2 (433.14937520000007)

Meleagrin

C23H23N5O4 (433.17499580000003)

CONFIDENCE isolated standard

Fenfangjine G

C15H24N5O8P (433.1362434)

12-[(2,4-dimethoxyphenyl)carbonyl]-6a,6b,10,11,11a,12-hexahydro-8,11-epoxyoxepino[4,5:3,4]pyrrolo[1,2-a]quinolin-7(8H)-one

C25H23NO6 (433.1525298)

relative retention time with respect to 9-anthracene Carboxylic Acid is 1.276 relative retention time with respect to 9-anthracene Carboxylic Acid is 1.275 relative retention time with respect to 9-anthracene Carboxylic Acid is 1.279

Fluvastatin sodium (Lescol)

C24H25FNNaO4 (433.16652220000003)

[(7R)-5-chloro-3-[(1E,3E,5S)-3,5-dimethylhepta-1,3-dienyl]-2-(2-hydroxyethyl)-7-methyl-6,8-dioxoisoquinolin-7-yl] acetate

NCGC00347765-02![(7R)-5-chloro-3-[(1E,3E,5S)-3,5-dimethylhepta-1,3-dienyl]-2-(2-hydroxyethyl)-7-methyl-6,8-dioxoisoquinolin-7-yl] acetate

C23H28ClNO5 (433.1655908000001)

C23H23N5O4_(3Z)-6-Hydroxy-3-(1H-imidazol-5-ylmethylene)-12-methoxy-7a-(2-methyl-3-buten-2-yl)-7a,12-dihydro-1H,5H-imidazo[1,2:1,2]pyrido[2,3-b]indole-2,5(3H)-dione

NCGC00380935-01_C23H23N5O4_(3Z)-6-Hydroxy-3-(1H-imidazol-5-ylmethylene)-12-methoxy-7a-(2-methyl-3-buten-2-yl)-7a,12-dihydro-1H,5H-imidazo[1,2:1,2]pyrido[2,3-b]indole-2,5(3H)-dione

C23H23N5O4 (433.17499580000003)

isochromophilone VI

C23H28ClNO5 (433.1655908000001)

MMV676571

C24H20N3O4F (433.14377720000005)

[(7R)-5-chloro-3-[(1E,3E,5S)-3,5-dimethylhepta-1,3-dienyl]-2-(2-hydroxyethyl)-7-methyl-6,8-dioxoisoquinolin-7-yl] acetate [IIN-based on: CCMSLIB00000846974]

NCGC00347765-02![(7R)-5-chloro-3-[(1E,3E,5S)-3,5-dimethylhepta-1,3-dienyl]-2-(2-hydroxyethyl)-7-methyl-6,8-dioxoisoquinolin-7-yl] acetate [IIN-based on: CCMSLIB00000846974]

C23H28ClNO5 (433.1655908000001)

[(7R)-5-chloro-3-[(1E,3E,5S)-3,5-dimethylhepta-1,3-dienyl]-2-(2-hydroxyethyl)-7-methyl-6,8-dioxoisoquinolin-7-yl] acetate [IIN-based: Match]

NCGC00347765-02![(7R)-5-chloro-3-[(1E,3E,5S)-3,5-dimethylhepta-1,3-dienyl]-2-(2-hydroxyethyl)-7-methyl-6,8-dioxoisoquinolin-7-yl] acetate [IIN-based: Match]

C23H28ClNO5 (433.1655908000001)

Ala Asp Asp Asn

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-carboxypropanamido]-3-carboxypropanamido]-3-carbamoylpropanoic acid

C15H23N5O10 (433.1444858)

Ala Asp Asn Asp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-carboxypropanamido]-3-carbamoylpropanamido]butanedioic acid

C15H23N5O10 (433.1444858)

Ala Asp Gln Thr

(2S,3R)-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-carboxypropanamido]-4-carbamoylbutanamido]-3-hydroxybutanoic acid